Alzheimer's Drug Discovery Foundation - research award programmes 2014 ($ 150,000)

The Alzheimer's Drug Discovery Foundation (ADDF) invites applications for the research award programmes. The upcoming deadline for submission of a full proposal for the “General Request for Proposals” is December 5, 2014. The Letter of Intent is due two weeks before the proposal deadline. Funding averages $150,000 per year.

Preclinical research funding priotrities for 2014 are:
• Drug Discovery - Target validation, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization-, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics;
• Biomarker Development - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.

ADDF funds drug discovery research programmes from investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.